Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Total Liabilities (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Total Liabilities for 8 consecutive years, with $145.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Liabilities fell 12.21% year-over-year to $145.5 million, compared with a TTM value of $145.5 million through Sep 2025, down 12.21%, and an annual FY2024 reading of $163.8 million, down 27.01% over the prior year.
  • Total Liabilities was $145.5 million for Q3 2025 at Bicycle Therapeutics, down from $163.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $234.1 million in Q2 2023 and bottomed at $81.8 million in Q1 2021.
  • Average Total Liabilities over 5 years is $156.0 million, with a median of $145.5 million recorded in 2025.
  • The sharpest move saw Total Liabilities surged 103.28% in 2021, then decreased 27.01% in 2024.
  • Year by year, Total Liabilities stood at $133.5 million in 2021, then rose by 4.71% to $139.8 million in 2022, then soared by 60.49% to $224.4 million in 2023, then fell by 27.01% to $163.8 million in 2024, then fell by 11.19% to $145.5 million in 2025.
  • Business Quant data shows Total Liabilities for BCYC at $145.5 million in Q3 2025, $163.3 million in Q2 2025, and $143.6 million in Q1 2025.